EU Research Commissioner Carlos Moedas sent the European Parliament and member states a €94.1 billion research budget proposal on Thursday outlining increases in basic science spending and a blueprint for a new innovation council to spawn transformative inventions.
The Commission’s budget breakdown for its next research programme, Horizon Europe, running between 2021 and 2027, devotes the biggest share of funding, €52.7 billion, to a series of projects to tackle climate change, boost digital technologies, improve food, handle other ‘global challenges’ and boost industrial competitiveness.
The balance of the €94.1 billion will go to fund fundamental science and innovation. The total for Horizon Europe represents about 10 per cent of government research funding across the EU.
“We’re aiming higher than ever,” the Commissioner said in an interview Wednesday. Horizon Europe follows the current Horizon 2020, which has provided around €77 billion in research funding. From the start, its competitions have been extremely popular and sometimes heavily over-subscribed.
Moedas is obviously thrilled about the proposed funding increase, which comes at the expense of EU investment in agriculture and poorer regions, the two main staples of the Brussels budget.
His colleagues can’t help but feel a little envious of the budget increase. One commissioner, riding a lift with some journalists in the Berlaymont on Wednesday, said: “When he goes to countries, he goes with money, while I go to issue moral imperatives.” Another, vice-president Jyrki Katainen, said on Thursday that Moedas was “lucky” to have his hands on the portfolio at this moment.
All the numbers announced by Moedas assume no contribution from the UK, although the country has expressed a wish to access the next EU research programme after it has left the EU next March, in exchange for a membership fee, and a large say in how priorities are set. Membership has still to be negotiated, though.
He promises several novelties in Horizon Europe, including ‘moonshot’ missions and new rules to ease foreign access.
Missions, which are not specified in the programme, will get somewhere between €5 – €10 billion, the Commissioner said. “It’s very difficult to create missions today for 2021-2027. So we are just going to set down criteria,” Moedas said. “It would be a little bit arrogant to define the missions now.”
Nevertheless, he gave two examples of possible missions that he feels the European public would get behind and support: finding a cure for Alzheimer’s disease, and creating zero-carbon boats.
The desire to create missions is also borne out of a niggling feeling the Commissioner has that there is not enough awareness or credit today for EU-funded research. “When IMI [the EU-funded Innovative Medicines Initiative] helped create a new Ebola vaccine in 2015, nobody knew it was us,” Moedas said.
Brussels also wants to tighten and, in its words, streamline the management of public-private research partnerships. “We have too many names, too many acronyms,” Moedas said.
Some ingenuity with numbers means the Commission is claiming a total research budget of €100 billion.
Image Credit: EC Horizon 2020
News This Week
Omicron subvariant BA.2 – which was dominant worldwide early this year, including in Hong Kong – replicates more swiftly than other strains and causes faster programmed cell death in human brains, a new study has found. [...]
The urgent need to remove excess carbon dioxide from Earth’s environment could include enlisting some of our planet’s smallest inhabitants, according to an international research team led by Michael Hochella of the Department of [...]
Blood pressure is a key vital sign that provides insight into our cardiovascular health. But blood pressure is typically measured only a few times per year by a clinician—and these measurements might not always [...]
A South African laboratory study using Covid-19 samples from an immunosupressed individual over six months showed that the virus evolved to become more pathogenic, indicating that a new variant could cause worse illness than [...]
For the past several months, Omicron subvariants BA.4 and BA.5 have dominated COVID-19 cases in the U.S. But now, there’s a class of new COVID subvariants on the rise and one in particular is getting plenty of [...]
Nucleic acid therapies involving DNA or RNA have significant potential to treat genetic disorders, infectious diseases, and cancer; however, research suggests that less than 1% of injected nucleic acid doses reach target cells in [...]
The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive drug [...]
Some wounds just won’t heal. Infections, diseases like diabetes, and suppressed immune systems often stack up to slow healing. Chronic wounds can last months and lead to anxiety and depression. In the worst cases, [...]